Indaptus Therapeutics Doses First Patient In Second Cohort Of Single Dose Ranging Study Of Decoy20
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics, Inc. (NASDAQ:INDP) has announced the dosing of the first patient in the second cohort of its INDP-D101 trial, which is testing the single dose of Decoy20. This cohort dose is a reduction from the previous one, based on the significant pharmacodynamic effect seen with the first cohort. The company is encouraged by the initial results and plans to move Decoy20 to a multi-dosing regimen.
September 19, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics is progressing with its INDP-D101 trial, testing Decoy20. The company's move to a multi-dosing regimen could potentially accelerate the development of Decoy20.
The news indicates that Indaptus Therapeutics is making progress in its clinical trial, which is a positive sign for the company. The move to a multi-dosing regimen could potentially accelerate the development of Decoy20, which could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100